This week Inari Medical announced that chief operating officer Drew Hykes will succeed Bill Hoffman as chief executive officer, effective 1 January 2023. Hykes will join Inari’s board of directors and Hoffman will also continue to serve on the board.
Hykes joined Inari in 2017 as chief commercial officer and has served as the company’s chief operating officer since 2020. Prior to Inari, he served in various leadership roles at both public and private medical device companies.
“A proven operating executive with broad functional, geographic and sector experience, [Hykes] has leveraged decades of experience in the medical device space to advance the company’s mission of effectively treating venous thromboembolism and transforming the lives of patients suffering from venous diseases,” a company press release reads.
“Drew is a talented leader, and he is the single best problem solver I have ever seen. More important, he is committed to the beautiful simplicity of our mission to impact the lives of our patients and their families in extraordinary ways, and to take care of our people along the way,” said chief executive officer Bill Hoffman. “Drew has established the scalable and repeatable systems that have produced best-in-class growth in patient treatments and revenue, and he has developed the cross-functional processes that have resulted in the explosion of new products and new markets we are just beginning to see. His leadership style and his skill set could not be better suited to the complexities that our next phase of growth will require. I am personally excited to have a front row seat to watch him lead the best team in the medical device space.”
“I am incredibly humbled to be named as Inari’s next CEO,” said chief operating officer Hykes. “Inari has undergone tremendous growth and change since I joined in 2017. From a venture backed, pre-commercial startup to an established public company with over 1,000 Clot Warriors, increasingly broad-based capabilities, and a shared ambition to change lives in the venous space and beyond. Despite all these changes, thanks to Bill’s leadership, we have maintained an unwavering commitment to our patients, our people and to big ideas. I could not be more committed to these same ideals, nor more enthusiastic about this next phase of our growth.”